Abstract
A theranostic, small-molecule-based prodrug, designed to be activated programmatically against hypoxic tumors, was successfully developed. The prodrug was stimulated to release the active chemotherapeutic drug in concurrent with a rhodol fluorophore in artificial hypoxia mimic conditions or an in vitro hypoxic environment. The extent of prodrug activation was monitored under the hypoxia condition by monitoring a fluorescence signal at 543 nm. The excellent therapeutic response and selective fluorescence labeling of biotin receptor overexpressed cancer cells ensured that the prodrug could be an effective strategy for the therapy of chronic hypoxic tumors.
Original language | English |
---|---|
Pages (from-to) | 4648-4655 |
Number of pages | 8 |
Journal | ACS Applied Bio Materials |
Volume | 2 |
Issue number | 10 |
DOIs | |
Publication status | Published - 2019 Oct 21 |
Keywords
- antitumor
- drug targeting
- hypoxia
- prodrug
- theranostic
ASJC Scopus subject areas
- Biomaterials
- Chemistry(all)
- Biomedical Engineering
- Biochemistry, medical